Stock Market | FinancialContent Business Page
FinancialContent fully hosted finance channel
Source: financialcontent.com
📰 Fiscus Ventures News
Fiscus Ventures News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Fiscus Ventures. Real-time updates on events, politics, business and more.
Vedanta announces millions in funding and new study
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
South Korea United States Atlantic Neptune Bernat Olle Administration For Strategic Preparedness Action Fund
Source: outsourcing-pharma.com
Verdana announces millions in funding and new study
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
Source: outsourcing-pharma.com
Investegate |PureTech Health PLC Announcements | PureTech Health PLC: Vedanta Gets $106M+ to Advance Microbiome Pipeline
Investegate announcements from PureTech Health PLC, Vedanta Gets $106M+ to Advance Microbiome Pipeline
Source: investegate.co.uk
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q... | April 25, 2023
Source: marketscreener.com
OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)
/PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today...
United States Orange County Convention Center Al Iskandariyah Prnewswire Oncoresponse Julie Rathbun Buchang Pharma
Source: prnewswire.com
Startup Ansa Bio lands $68M to go long with enzymes approach to DNA synthesis
The DNA currently used in genetic medicines research is synthesized by chemical methods. Ansa Biotechnologies employs faster and less expensive enzymes-based technology, and the startup has raised capital to scale up operations as it prepares to launch its service.
Daniel Lin Arlow Sebastian Palluk Humboldt Fund University Of California At Berkeley California Based Ansa Nature Biotechnology
Source: medcitynews.com
Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing to Power the Next Era of D
Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by synthetic DNA from biologic drugs to biomanufacturing, and DNA-based data storage.Funding will advance next-generation technology platform, expand R&D and manufacturing facilities, grow...
Source: pharmiweb.com
Ansa Biotechnologies Closes $68M Series A Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Daniel Lin Arlow Sebastian Palluk Humboldt Fund Ansa Biotechnologies Northpond Ventures Blue Water Life Science Advisors
Source: finsmes.com
SomaLogic Raises Additional $81M to Series A Financing Totaling $214M
SomaLogic Raises Additional $81M to Series A Financing Totaling $214M SomaLogic, Inc., a Boulder, CO-based global developer of proteomic discovery and applications for biomedical discovery and clinical diagnostics, added $81M to Series A raise which now totals $214M. In this second close, additional financial investors include Janus Henderson Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures, Boston Millennia Partners and Millennium Management. Stra...
United States Roy Smythe T Rowe Price Associates Inc Redmile Group Solution Innovators Ltd Somalogic Inc
Source: finsmes.com